Microbot Medical

Company Overview

Snapshot

Founded in November 2010 by Harel Gadot, Microbot Medical operates with 11–50 employees. The company has raised $90.52 million across 15 funding rounds from 2 investors. In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System.

Business overview

Microbot Medical specializes in developing transformational robotic technologies, primarily for the endovascular space. Its core product, the LIBERTY Robotic System, is designed as the world’s first single-use endovascular robotic system, aiming to increase access to robotic technology and revolutionize endovascular procedures. The company serves the medical devices and healthcare industries, focusing on sectors such as gastroenterology, vascular, neurology, and cardiovascular applications.

Strategic signal

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System. This regulatory approval is a significant validation of the company's technology and paves the way for commercialization, signaling to investors a critical step towards market entry and potential revenue generation in the highly competitive medical robotics sector.

Company Intelligence Q&A

What is Microbot Medical's primary focus?

Microbot Medical focuses on developing robotics-assisted medical technologies, particularly for the endovascular space, with its flagship LIBERTY Robotic System.

When did Microbot Medical go public?

Microbot Medical initiated trading on NASDAQ as 'MBOT' in November 2016, following a merger transaction.

What was a significant recent regulatory milestone for Microbot Medical?

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System.

What is the LIBERTY Endovascular Robotic System?

The LIBERTY Endovascular Robotic System is the world's first single-use endovascular robotic system designed to streamline endovascular procedures and increase access to robotic technology.

What was a key acquisition made by Microbot Medical?

In October 2022, Microbot Medical acquired NitiLoop, strengthening its LIBERTY robotic system portfolio with novel FDA-cleared devices.